The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma.
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; AVEO; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; Synthekine; Werewolf Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Avivit Peer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Janssen; Medison; MSD; Pfizer; Roche; Sanofi/Aventis; Takeda; Teva
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Janssen; Medison; MSD; Pfizer; Roche
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Pfizer
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Adagene; Agenus; Asher Biotherapeutics; AstraZeneca; Aveo; Bristol-Myers Squibb; Calithera Biosciences; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; GlaxoSmithKline; Idera; Iovance Biotherapeutics; Leads Biolabs; Merck; Novartis; Oncorena; PACT Pharma; Pfizer; Pneuma Respiratory; Pyxis; Sanofi; Scholar Rock; Seagen; Simcha Therapeutics; Surface Oncology; Takeda; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Jerry Cornell
Employment - Merck
 
Rodolfo F. Perini
Employment - MSD
Stock and Other Ownership Interests - MSD
 
Kenneth F. Grossmann
Employment - Merck
Consulting or Advisory Role - Array BioPharma; Bristo-Meyers Squibb; Natera; Novartis
 
Howard Gurney
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Merck Serono
Travel, Accommodations, Expenses - AstraZeneca